Information Provided By: 
Fly News Breaks for February 20, 2019
AMGN, CYTK
Feb 20, 2019 | 14:27 EDT
After Cytokinetics (CYTK) announced that partner Amgen (AMGN) has initiated a Phase 1 study of cardiac troponin activator AMG 594, Piper Jaffray analyst Edward Tenthoff said he envisions the two developing AMG 594 in heart failure with reduced ejection fraction, or HFrEF. The analyst, who noted he awaits the futility analysis of the Phase 3 GALACTIC-HF trial of omecamtiv mecarbil in HFrEF patients, which is expected to be reported in the first half of the year, reiterated an Overweight rating and $12 price target on Cytokinetics shares.
News For CYTK;AMGN From the Last 2 Days
There are no results for your query CYTK;AMGN
